Company Overview - Chicago Atlantic BDC has closed over $3.2 billion in loans since its platform inception[10] - The company's total portfolio investment value is $311 million[10] - The gross weighted-average yield of the company's debt investments is 15.8%[10] - 100% of the company's current debt investments are senior secured[10] Financial Performance - Gross investment income for the quarter ended September 30, 2025, was $15.1 million[24] - Net investment income for the same quarter was $9.5 million, or $0.42 per share[24] - Net asset value at the end of the period was $302.9 million, or $13.27 per share[24] Portfolio Composition and Strategy - 76% of the investment portfolio is allocated to cannabis-related businesses, while 24% is in non-cannabis sectors[29] - 71% of the debt portfolio is protected from further interest rate declines due to fixed rates or rate floors[15, 42] - Internally agented deals account for 83.8% of the portfolio companies[27]

Core Insights - Canopy Growth's stock surged 7.34% following the release of its Q2 fiscal 2026 results, indicating strong investor interest [1] - The company outperformed analyst forecasts, driven by robust performance in the Canadian adult-use and medical cannabis segments [2] - Operational improvements and disciplined cost management contributed to narrowing losses and lifting gross margins [2] Company Performance - Canopy Growth's Canadian operations continued to grow despite supply chain challenges in Europe, supported by innovative vape products and an increase in medical cannabis patients [3] - The company's evolving strategy and resilience in core markets are highlighted by these results [3] - The stock's future performance will depend on sustaining margin expansion, strengthening international operations, and solidifying its medical leadership [4] Market Position - Canopy Growth, based in Smiths Falls, Canada, has a market cap of approximately $287 million and serves both medical and recreational cannabis markets [5] - The product lineup includes high-THC cannabis flower, infused pre-rolls, advanced vape technology, and cannabis edibles [5] - Despite a strong product portfolio, CGC shares have declined 70.18% over the past 52 weeks, with a 14% drop in the last month, contrasting with a 14.4% gain in the S&P 500 Index during the same period [6]

Core Insights - Auxly Cannabis Group Inc. reported strong financial results for Q3 2025, with net revenues of $39.9 million, a 20% increase year-over-year, driven by higher volumes and improved pricing across its product portfolio [9][5][19] - The company achieved a gross profit of $28.2 million, resulting in a gross profit margin of 71% for the quarter, up from 52% in Q3 2024 [11][12] - Adjusted EBITDA grew by 48% to $12.3 million, reflecting improved operational efficiency and cost control [3][21] Financial Highlights - Net revenues for Q3 2025 were $39.9 million, compared to $33.3 million in Q3 2024, marking a 20% increase [9][5] - Gross margin on finished cannabis inventory sold improved to 56% from 47% in Q3 2024 [12][11] - Net income for Q3 2025 was $20.5 million, a significant increase of 533% compared to $3.2 million in Q3 2024 [19][20] - Cash flow from operations before working capital changes was $11 million, an increase of 82% year-over-year [5][3] Operational Highlights - The company maintained a strong market position, being the third-largest licensed producer in Canada by market share [5] - Back Forty was recognized as the number one cannabis brand in Canada, with Liquid Imagination and Fire Breath 28g being the top-selling SKUs [5][3] - Auxly's operational efficiency led to a 48% year-over-year growth in Adjusted EBITDA, with margins reaching 31% [3][21] Strategic Outlook - Auxly aims to leverage its strong financial position to pursue organic growth opportunities and maintain profitability through innovation and cost control [22][24] - The company plans to allocate $2.0 million to $2.5 million of cash flow from operations towards capital projects in 2025 [25] - Auxly is exploring international market opportunities, supported by its strong brands and scalable production capabilities [26][27]

Core Insights - Rubicon Organics Inc. reported strong financial results for Q3 2025, with net revenue of CAD 15.6 million, a 16% increase year-over-year, and Adjusted EBITDA of CAD 1.7 million, reflecting operational scale and cost control [3][8][9] Financial Performance - Q3 2025 net revenue reached CAD 15.6 million, up from CAD 13.5 million in Q3 2024, while year-to-date (YTD) revenue for 2025 was CAD 43.0 million, a 25% increase compared to the same period in 2024 [9][12] - Adjusted EBITDA for Q3 2025 was CAD 1.7 million, with YTD Adjusted EBITDA at CAD 3.8 million, marking the sixth consecutive quarter of positive Adjusted EBITDA [3][9][12] - Gross profit for Q3 2025 was CAD 8.0 million, with a gross profit margin of 33.7%, compared to 32.4% in Q3 2024 [12] Market Position and Growth Strategy - The company has a national market share of 6.2% in premium flower and pre-rolls, 13.2% in premium vapes, and 16.0% in premium edibles for Q3 2025 [9] - Rubicon's acquisition of the Cascadia Facility is expected to increase production capacity by over 40%, supporting future growth in both domestic and international markets [7][11] - The company has successfully shipped to three international markets in the fiscal year, indicating a strategic focus on global expansion [9] Operational Highlights - The company has begun investing in talent and foundational initiatives to support growth as it prepares to realize revenue from the Cascadia Facility in 2026 [2][3] - Cash flow from operations for Q3 2025 was CAD 0.5 million, with total current assets amounting to CAD 35.6 million as of September 30, 2025 [9][12] Future Outlook - For fiscal 2025, the company forecasts growth in both net revenue and Adjusted EBITDA, despite anticipated one-time costs related to the Cascadia Facility [11][20] - The company remains confident in its long-term value creation potential, driven by ongoing expansion and strategic initiatives [11][20]

Core Viewpoint - The recent funding bill passed by Congress includes a controversial provision that re-criminalizes several THC-infused and hemp-derived products, which were legalized under the 2018 Farm Bill, raising concerns within the hemp and cannabis industry [1][2]. Group 1: Legislative Changes - A last-minute provision in the funding package criminalizes certain THC-infused and hemp-derived products, reversing the legalization established by the 2018 Farm Bill [2]. - The 2018 law defined hemp as containing less than 0.3% delta-9 THC, but the new provision targets products that contain less than 0.3% delta-9 THC but exceed 0.3% total THC concentration, which may be intoxicating [2][3]. Group 2: Industry Impact - Senator Rand Paul expressed concerns that the new provisions could eliminate nearly 100% of legal hemp products overnight, potentially leading to job losses and overriding 23 state laws regulating these products [3][4]. - The hemp industry has been a crucial support for farmers facing rising costs, and the new regulations are seen as a move towards prohibition rather than addressing issues with bad actors in the market [4]. Group 3: Market Reactions - The impact on stocks within the industry is mixed; some multi-state operators not involved in Delta-8 beverages or hemp-derived THC gummies may benefit from reduced competition, while companies like Tilray Brands Inc. have faced significant declines [5][6]. - Specific stock performances include Tilray Brands Inc. down 4.65% and Curaleaf Holdings Inc. down 1.76%, with year-to-date performances showing Tilray down 15.75% and Curaleaf up 69.51% [7].

Core Insights - Rubicon Organics Inc. has appointed Glen Ibbott as Chief Financial Officer and Corporate Secretary, highlighting his extensive experience in the cannabis industry and previous role as CFO of Aurora Cannabis [1][2][3] Company Overview - Rubicon Organics is a licensed producer focused on cultivating and selling organic certified and premium cannabis products, positioning itself as a leader in the Canadian market [1][4] - The company operates a vertically integrated model with a strong national distribution network, featuring trusted brands such as Simply Bare™ Organics and 1964 Supply Co.™ [4] Leadership and Strategic Direction - Glen Ibbott has been recognized for his exceptional leadership and strategic insight during his interim CFO tenure, contributing significantly to the company's growth and operational scaling [2][3] - Ibbott's background includes over 25 years in financial leadership roles, with notable achievements at Aurora Cannabis, including international expansion and delivering recurring EBITDA [3] Production Capacity and Growth Potential - Rubicon's production capabilities are anchored by its Pacifica facility in Delta, BC, and the newly acquired Cascadia facility in Hope, BC, which will increase production capacity by over 40% [5] - The company is well-positioned to capitalize on the growing global demand for high-quality cannabis, supported by proprietary genetics and certifications for international distribution [5][6] Market Position and Financial Performance - As the Canadian cannabis market rationalizes, Rubicon Organics distinguishes itself through disciplined execution, brand equity, and consumer loyalty, driving consistent revenue growth and positive Adjusted EBITDA [6] - The company represents a combination of category leadership, operational strength, and long-term growth potential in the premium cannabis segment [6]

Core Insights - Rubicon Organics Inc. has appointed Glen Ibbott as Chief Financial Officer and Corporate Secretary, highlighting his extensive experience in the cannabis industry and previous role as CFO of Aurora Cannabis [1][2][3] Company Overview - Rubicon Organics is a licensed producer focused on cultivating and selling organic certified and premium cannabis products, positioning itself as a leader in the Canadian market [1][4] - The company operates a vertically integrated model with a strong national distribution network, featuring trusted brands such as Simply Bare™ Organics and 1964 Supply Co.™ [4] Leadership and Strategic Direction - Glen Ibbott brings over 25 years of leadership experience in publicly-traded life sciences and cannabis companies, having played a crucial role in Aurora Cannabis's growth and international expansion [3] - The CEO, Margaret Brodie, expressed confidence in Ibbott's strategic insight and financial acumen, which have already positively impacted the company's operations [2] Production and Capacity Expansion - Rubicon's production base is anchored by its Pacifica facility in Delta, BC, and is set to expand by over 40% with the acquisition and licensing of the Cascadia facility in Hope, BC [5] - The company is positioned to support future growth in both domestic and export markets through proprietary genetics and award-winning products [5] Market Position and Growth Potential - As the Canadian cannabis market rationalizes and global demand for high-quality cannabis increases, Rubicon's disciplined execution and brand equity differentiate it from competitors [6] - The company has demonstrated consistent revenue growth and positive Adjusted EBITDA, indicating strong operational performance and long-term growth potential [6]

Core Insights - Planet 13 Holdings Inc. reported a significant decline in revenue and increased net loss for Q3 2025, indicating operational challenges and market pressures [4][5][11]. Financial Performance - Q3 2025 revenue was $23.3 million, down 27.6% from $32.2 million in Q3 2024, attributed to price compression and a weaker consumer environment in Nevada, along with increased competition in Florida [5][9]. - The net loss for Q3 2025 was $44.0 million, compared to a net loss of $7.4 million in the same quarter last year, which included a $29.8 million non-cash impairment loss [4][5][9]. - Adjusted EBITDA loss was $4.1 million, a significant decline from an adjusted EBITDA of $1.3 million in Q3 2024, driven by lower gross profit and operating leverage [5][9]. Operational Adjustments - The company has taken decisive actions to address its cost structure, significantly reducing selling, general, and administrative (SG&A) expenses, and has implemented impairment and inventory reserve charges to clean up its balance sheet [2][3]. - Exiting California operations is expected to eliminate a persistent cash drain, allowing the company to focus on Nevada and Florida, where it has competitive advantages [3]. Balance Sheet Overview - As of September 30, 2025, total assets were $158.5 million, down from $206.7 million at the end of 2024, while total liabilities increased to $103.9 million from $94.0 million [6][22]. - Cash reserves decreased to $17.2 million from $23.4 million, indicating liquidity challenges [5][22]. Recent Developments - The company launched a revamped loyalty program and introduced new products in Florida, including HaHa branded fast-acting soft chews [13]. - Planet 13 opened two new dispensaries in Florida and closed its California operations, marking a strategic shift in its market focus [3][13].

NEW YORK and TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, today reported its financial results for the third quarter ended September 30, 2025. The Company’s Quarterly Report on Form 10-Q (the “Quarterly Report”), which includes its unaudited interim condensed consolidated financial statements for the three and nine months ended Se ...

Third quarter results reflect temporary planned scaled back in new planting and wholesale productionCompany remains on track to return to full production at existing greenhouses in the first quarter of 2026, by year-end 2025 will have the most cannabis acreage planted in the Company’s historyPreviously announced $95 per pound of biomass full year production cost target remains intactConference Call to be held today November 12, 2025 at 5:00 p.m. ET LONG BEACH, Calif. and TORONTO, Nov. 12, 2025 (GLOBE NEWSWI ...